Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly inks cancer-fighting technology deal. We believe Immunocore's ImmTAC platform has the potential to do just that, said Jan Lundberg, on the co-discovery…
FierceBiotech reported the Lilly-Immunocore co-discovery deal alongside Immunocore's parallel pacts with Genentech, GSK and MedImmune, framing the year as a…
Immunocore disclosed in its 10-K that the Lilly collaboration was terminated in 2022 and 'no further revenue is expected from Lilly,' a buyer-aligned negative…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Lilly partnered with Oxford-based Immunocore in an option-and-license agreement spanning multiple ImmTAC bispecific T-cell-receptor cancer candidates, with $45M up front and the rest in development and commercial milestones plus tiered royalties. One of four major-pharma ImmTAC pacts (also GSK, Genentech, AstraZeneca) signed by Immunocore in 2014.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Immunocore Limited (this deal) | 2014 | $365M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2014 deals · Eli Lilly and Company deals · Oncology deals